Predictors of bone mineral loss in patients with ovarian cancer treated with anticancer agents
Predictors of bone mineral loss in patients with ovarian cancer treated with anticancer agents
复制标题
DOI：
10.1016/s0029-7844(97)00124-5
复制
发表时间：
1997-07-01
影响因子：
7.2
通讯作者：
Nagata, Y
中科院分区：
文献类型：
--
作者：
Douchi, T;Kosha, S;Nagata, Y
目的：探讨预测肿瘤化疗期间骨矿物质流失的因素。方法：研究了15例卵巢癌患者（平均年龄38.2±7.8岁，范围30-46岁），她们在手术后每4周接受顺铂-阿霉素-环磷酰胺治疗6个周期。化疗前后采用双能x线骨密度仪测定腰椎（L2-L4）骨密度（BMD）。15名年龄相仿、因其他原因切除卵巢的女性作为对照组。这些患者都没有接受过激素治疗。比较两组患者同期骨密度变化百分比（BMD%）。化疗组采用双能x线吸收仪测量总脂肪量、体脂比、总瘦质量、瘦百分比、躯干脂肪/腿部脂肪比。同时计算化疗期间的瘦损。这些变量在化疗前和结束时进行比较。通过单变量和逐步回归分析确定基线变量与BMD%的可能相关性。结果：平均（+/-标准差）BMD在化疗6个周期后下降至87.4 +/- 2.1%，对照组在6个月后下降至97.6 +/- 0.4%，但化疗组下降幅度最大（P < 0.001）。虽然在单变量分析中，基线瘦体重、基线骨密度、体重和化疗期间瘦体重损失与骨密度%相关，但在逐步回归分析中，基线瘦体重仍然显著。结论：基线瘦体重预测抗肿瘤化疗的骨矿物质损失。(C) 1997年由美国妇产科医师学会出版。
Objective: To identify factors predicting bone mineral loss during anticancer chemotherapy.Methods: Fifteen women (mean age 38.2 +/- 7.8 years; range 30-46 years) with ovarian cancer who had been treated with cisplatin-adriamycin-cyclophosphamide for six cycles every 4 weeks following surgical cytoreduction were studied. Bone mineral density (BMD) of the lumbar spine (L2-L4) was measured by dual-energy x-ray absorptiometry before and after chemotherapy. Fifteen age-matched women whose ovaries had been removed surgically for other reasons served as controls. None of the patients had received hormonal treatment. The two groups were compared for percentage change of BMD (BMD%) over the same period. In the chemotherapy group, total fat mass, body fat ratio, total lean mass, percent lean, and ratio of trunk fat to leg fat were measured by dual-energy x-ray absorptiometry. Lean loss during chemotherapy was also calculated. These variables were compared before and at the end of chemotherapy. Possible correlations of baseline variables with BMD% were determined in univariate and stepwise regression analysis.Results: Mean (+/- standard deviation) BMD decreased to 87.4 +/- 2.1% after six cycles of chemotherapy and 97.6 +/- 0.4% after 6 months in controls, but the greatest decrease was observed in the chemotherapy group (P < .001). Although baseline lean mass, baseline BMD, body weight, and lean loss during chemotherapy were correlated with BMD% in univariate analysis, baseline lean mass was still significant in stepwise regression analysis.Conclusion: Baseline lean mass predicts bone mineral loss with anticancer chemotherapy. (C) 1997 by The American College of Obstetricians and Gynecologists.